CE / CME
In this certified on-demand webcast, experts discuss strategies for overcoming endocrine resistance in HR+/HER2- metastatic breast cancer (MBC), focusing on the evolving treatment landscape with CDK4/6 inhibitors, mechanisms of resistance, and emerging therapies like SERDs, PROTACs, and PI3K/AKT/mTOR pathway inhibitors. The session emphasizes personalized treatment approaches, clinical trial data, and optimizing sequencing to improve patient outcomes.
Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits
Nurse Practitioners/Nurses: 1.50 Nursing contact hours
Pharmacists: 1.50 contact hours (0.15 CEUs)
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Released: June 20, 2025
Expiration: December 19, 2025
Share
Provided by Clinical Care Options, LLC.
Supported by educational grants from AstraZeneca, Lilly and Stemline Therapeutics, Inc.
AstraZeneca
Lilly
Stemline Therapeutics, Inc.
This educational activity is intended for medical oncologists, nurses, nurse practitioners, pharmacists, physician associates, and other healthcare professionals who care for patients with HR-positive/HER2-negative advanced breast cancer.
The goal of this activity is to improve the knowledge, confidence, and competence of learners in applying available clinical data on oral therapies to treatment selection and supportive care for patients with HR-positive/HER2-negative advanced breast cancer harboring ESR1 or PIK3CA/AKT1/PTEN alterations that progressed on or after first-line endocrine therapy. Secondary goals include improving patient engagement, aligning treatments to patient needs, and increasing patient satisfaction with care.
Upon completion of this activity, participants should be able to:
Educate patients and colleagues on the biologic rationale behind using oral SERDs and PI3K/AKT inhibitors in HR-positive/HER2-negative ABC progressing on a first-line CDK4/6 inhibitor plus ET
Evaluate the potential clinical use of ctDNA monitoring for early detection of disease progression in patients with HR-positive/HER2-negative ABC
Design individualized treatment plans for patients with HR-positive/HER2-negative ABC progressing on first-line endocrine therapy based on biomarker testing results, patient factors, clinical data, and expert recommendations
Appraise emerging data on novel oral SERDs and precision medicine approaches and their potential application to clinical practice for patients with HR-positive/HER2-negative ABC harboring ESR1 and/or PIK3CA/AKT/PTEN alterations
Collaborate with multidisciplinary colleagues, patients, and caregivers to minimize the risk of treatment-related toxicities in patients with progressive HR-positive/HER2-negative ABC
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary AuthorErica L. Mayer, MD, MPH, FASCO: consultant/advisor/speaker: AstraZeneca, Lilly, Novartis.
Ruth M. O’Regan, MD: consultant/advisor/speaker: Biotheranostics, Gilead, Lilly, Puma, REGOR Pharmaceuticals; researcher: Novartis, Puma.
Joyce O’Shaughnessy, MD: consultant/advisor: AADI Bioscience, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, BioNTech, Bristol Myers Squibb, Daiichi Sankyo, Duality, Eisai, Ellipses, Exact Sciences, G1 Therapeutics, Genentech, Gilead, Guardant Health, Hibercell, Jazz, Johnson & Johnson, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Sanofi, Seagen, Stemline, Summit, Tempus, TerSera.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.
Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Sobi, Stemline.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 20, 2025, through December 19, 2025:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-25-231-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 19, 2025. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
CME Passport
The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.